Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

1.080 -0.040 (-3.57%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
The eAArly DETECT results reported a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82% 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
mRNA Is Promising A Breakthrough In Fighting Cancer ↗
When it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as it... 
Via Benzinga
News headline image
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
From Mainz BioMed NV
Via GlobeNewswire
News headline image
The Pharmaceutical Industry Finds Itself At A Historical Crossroads ↗
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: 
Via Benzinga
News headline image
MYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023 ↗
MYNZ stock results show that Mainz Biomed beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Mainz Biomed Reports Full Year 2023 Financial Results
ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of $7.1 Million 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era ↗
Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic. 
Via Benzinga
News headline image
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening ↗
When it comes to cancer, one cannot overestimate the importance of early detection. Especially when it comes to colorectal and endometrial cancer that even big pharma companies don’t have a good track... 
Via Benzinga
News headline image
Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment ↗
Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several... 
Via Benzinga
Topics Intellectual Property
News headline image
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
Partnership Brings Pioneering Approach to Incorporating Advanced Colorectal Cancer Detection Into Country’s Healthcare System 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front ↗
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine... 
Via Benzinga
News headline image
Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
Company opens own physician-led laboratory, ‘European Oncology Lab’ (EOL), thereby offering ColoAlert® as a laboratory medical service directly to physicians and patients 
From Mainz BioMed NV
Via GlobeNewswire
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
--News Direct-- 
Via News Direct
Topics Death
News headline image
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle ↗
On Tuesday, Pfizer Inc (NYSE: PFE) reported mixed results for its fourth quarter. Last year, Pfizer has responded to concerns related to its COVID-19 products being the rearview mirror with a... 
Via Benzinga
News headline image
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge ↗
The global population is experiencing a scary increase in colorectal cancer, especially among young people. Colorectal cancer (CRC) diagnoses have been steadily rising since the 1990s; in 1995 the... 
Via Benzinga
Topics Death
News headline image
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
From Mainz BioMed NV
Via GlobeNewswire
News headline image
2024 Marks a New Era Of Pharmaceutical Innovation ↗
With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned... 
Via Benzinga
News headline image
Mainz Biomed Provides Year-End Corporate Review 2023
From Mainz BioMed NV
Via GlobeNewswire
News headline image
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer ↗
During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc. 
Via Benzinga
News headline image
Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study ↗
 
Via Benzinga
News headline image
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
Hermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three of Their German Locations, Namely Ulm, Ulm-Nord, and... 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.